PM Modi reviews progress under TB elimination campaign
Prime Minister Narendra Modi on Tuesday chaired a meeting to review progress of the tuberculosis (TB) elimination campaign.
The intensified campaign to eliminate TB started in December last year.
The meeting was attended by Union health minister, JP Nadda, health secretary, Punya Salila Srivastava, and senior officials from the Prime Minister's Office (PMO).
'Chaired a meeting on India's mission to eliminate TB. Driven by active public participation, the movement has gained significant momentum over the last few years. Our government remains committed to working closely with all stakeholders to realise the vision of a TB-free India,' wrote the PM on microblogging site X.
India has set a TB-elimination target for 2025, five years ahead of the global target of 2030.
TB is one of the leading infectious diseases globally, and in India, nearly 2.6 million new patients were notified, last year, according to the government data.
Under the National Tuberculosis Elimination Programme (NTEP), India has strengthened its TB response with advanced diagnostics, innovative policies, private sector partnerships, and a patient-first approach.
Key drivers include record-high case reporting, better diagnostics, financial support for patients, and strong multi-sector collaboration.
Globally, nearly 20% of global TB incidence, which is the number of new cases, is attributable to undernutrition, increasing to at least a third in India.
Indian government has been proactive in providing nutritional support to TB patients under its Ni-Kshay Poshan Yojana.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
Dr Reddy's, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global (generic name is pembrolizumab ), manufactured and marketed by Merck & Co , is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, Hyderabad-based DRL said in a statement on to certain exceptions, each party will have the right to commercialise the product traditional generics, which often face automatic patent infringement claims, biosimilars are developed more like original drugs, complete with clinical trials and patent disclosures, giving them a better chance of overcoming legal challenges. Also, Merck's core patents on pembrolizumab in the US are expected to start expiring around 2028.'This (collaboration) demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide,' Erez Israeli, chief executive of DRL, said.Róbert Wessman, chairman and CEO of Alvotech, said, 'The agreement enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide.'Keytruda is approved in the US to treat 40 cancers, unlike most medicines that treat a few indications or medical India, it is approved for use in 17 indications across 10 cancers or tumour types. Oncologists mostly prescribe it to treat certain types of lung cancers, followed by gastrointestinal cancer, triple-negative breast cancer and head and neck helps the body's immune system, which is the T-cells, to detect and fight cancer cells that hide and spread in organs.'Oncology has been a top focus therapy area for us, and this collaboration will enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ,' Israeli has been out of reach for most patients in India due to its exorbitant cost – roughly about Rs 2 lakhs for each dose. However, with Merck's patent set to expire in a few years and with Indian drug manufacturers looking to come up with more affordable versions of the drug it may play a crucial role in widening adoption across a larger cohort of patients.
India.com
3 hours ago
- India.com
Low Effort, High Flavor: Paneer Salad Bowls For Every Day
Anaika Sohal Jun 05, 2025 This healthy bowl is made with grilled tandoori paneer cubes with cucumber, onions, cherry tomatoes, and mint-yogurt dressing. An Indian twist to the bowl by adding sauteed paneer in Indian spices over shredded lettuce, corn, bell peppers, and lemon juice. A quick and healthy breakfast recipe made from crumbled paneer tossed with cooked quinoa, parsley, olives, and a light olive oil-lime vinaigrette. A different unique variety of paneer bowl tempered with mustard seeds and curry leaves, served with grated carrot, coconut, and soaked moong dal. Tasty and healthy version of paneer bowl with soft paneer cubes with avocado slices, microgreens, roasted sunflower seeds, and tahini dressing. A tropical bowl made with cubed paneer, cherry tomatoes, cucumber, lettuce, and a drizzle of lemon-garlic hummus. For this recipe add baked or air-fried chilli paneer with sautéed broccoli, red cabbage, and a sesame-soy glaze. Read Next Story
Time of India
4 hours ago
- Time of India
NTET 2025 registration begins at exams.nta.ac.in: Apply online by this date, check direct link here
The National Testing Agency ( NTA ) has commenced the registration process for the National Teachers Eligibility Test (NTET) 2025, aimed at postgraduates in Indian systems of medicine and homoeopathy aspiring to become educators. The examination is scheduled for July 17, 2025. Aspirants seeking to appear for the exam must possess postgraduate qualifications in disciplines such as Ayurveda, Siddha, Unani, or Homoeopathy. Acceptable combinations include degrees like BAMS with MD/MS in Ayurveda, BHMS with MD in Homoeopathy, and BUMS with MD in Unani, among others. Additionally, qualifications like MSc in Anatomy, Physiology, Biochemistry, and Master of Public Health are recognized. NTET 2025 Important Dates Candidates appearing for the NTET 2025 exam are advised to check all the important dates mentioned below: Application Period: June 4 to June 23, 2025 (until 11:50 PM) Fee Payment Deadline: June 24, 2025 (until 11:50 PM) Correction Window: June 25 to June 27, 2025 Examination Date: July 17, 2025 NTET 2025 Application Fees To register for the NTET 2025 examination, applicants must fill the registration form along with the application fee. Check category wise application fee amount below: General Category: Rs. 4,000 General-EWS/OBC-NCL: Rs. 3,500 SC/ST/PwD/Third Gender: Rs. 3,000 Fees can be paid online through the official portal. How to apply for NTET 2025? Here is how candidates can register online for NTET 2025 examination: Visit the official website: Register and fill out the application form. Upload necessary documents, including a recent photograph, signature, educational certificates, and valid ID proof. Pay the application fee online. Submit the form and retain a copy for future reference. Direct link to apply for NTET 2025 For more details, candidates should refer to the official information bulletin available on the NTA website. Ready to navigate global policies? Secure your overseas future. Get expert guidance now!
